Short answer
Tectonic Therapeutic, Inc. (TECX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only standard exhibit incorporation and liability language.
Tectonic Therapeutic, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only standard exhibit incorporation and liability language
- No operating results, financial figures, reporting period, or investor-impacting disclosures included
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 earnings update: net loss $22.3M versus $20.0M, with R&D expense rising to $18.0M
- TX45 APEX Phase 2 enrollment complete: 191 patients, including 137 enriched CpcPH patients; topline results expected early Q1 2027
- Independent monitoring committee recommended TX45 continuation without modification after reviewing approximately 80% of expected exposure
- TX2100 Phase 1a single-dose cohorts completed; topline safety, tolerability, and pharmacokinetic results expected by end-Q3 2026
- Cash $227.1M, including approximately $11.7M ATM proceeds; management projects runway into Q1 2029 through key readouts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tectonic Therapeutic, Inc. 8-K filings
Get the next TECX 8-K as it lands
Follow TECX for push alerts, or ask the research agent what this filing means.